Skip to content

Prevalence of Hyperventilation Syndrome in Difficult Asthma

Prevalence of Hyperventilation Syndrome in Difficult Asthmatics Uncontrolled Despite a Daily Maximal Doses of Inhaled Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01862289
Acronym
PRESH
Enrollment
151
Registered
2013-05-24
Start date
2013-04-28
Completion date
2016-10-18
Last updated
2018-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Difficult Asthma, Hyperventilation Syndrome, Severe Persistent Asthma

Keywords

difficult asthma, hyperventilation syndrome, prevalence

Brief summary

Most of asthmatics patients remain uncontrolled despite an inhaled steroids treatment. Chronic hyperventilation syndrome (also called Idiopathic Hyperventilation) occurs in 20 to 40% of asthmatic patients. The purpose of the study is to assess the prevalence of chronic hyperventilation syndrome in a specific population of difficult-to-treat asthmatics patients, those who receive daily high doses of inhaled steroids (≥ 1000 µg of fluticasone with an additional treatment by a long-acting beta 2-agonist (LABA) and who remain uncontrolled (Asthma control test (ACT) \< 18). We plan to realize a systematic assessment of the diagnosis of chronic hyperventilation syndrome with the Nijmegen questionnaire, blood gases at rest, hyperventilation testing and Cardiopulmonary Exercise Testing(CPET). We also will collect demographic information as well as information about asthma history, asthma control and treatment.

Detailed description

There is only one visit. During this visit, each patient will complete self-questionnaires like Nijmegen, Hospital Anxiety and Depression Scale(HAD), Short-Form 36(SF36), and Asthma Quality of Life Questionnaire (AQLQ), The participants will have baseline spirometry and fractional exhaled nitric oxide measured at expiratory flow of 50 mL/s (FENO50), blood gases at rest, an hyperventilation challenge and Cardiopulmonary Exercise Testing(CPET) to determine accurately the presence or not of chronic hyperventilation syndrome. The diagnosis is confirmed by two positive tests (Nijmegen, Hyperventilation challenge and blood gases) and the final decision of a medical committee. The first step is to determine the prevalence oh this syndrome in this specific population. The second step is to assess the sensitivity, the specificity, the false positive rate and the false negative rate of the different parameters measured during the tests.

Interventions

OTHERDiagnostic of chronic hyperventilation syndrome

Nijmegen questionnaire, Hyperventilation challenge and blood gases

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* men and women, * aged more than 18, * non smokers for two years or longer, less than 10 pack/years smoking history, * physician-diagnosed asthma, * uncontrolled asthma with Asthma control test (ACT) \< 18, * historical of FEV1 reversibility, * daily inhaled steroids treatment by at least 2000microg eq beclomethasone, * Forced expiratory volume in 1 second (FEV1) \> 50% predicted value

Exclusion criteria

* other chronic pulmonary disease, * vocal cord dysfunction, * pregnancy, * Participation in another interventional research trial, * unable to provide consent, * asthma exacerbation within the last 4 weeks

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic of the hyperventilation syndromeUp to 4 hoursvalue of Nijmegen questionnaire, of blood gases at rest, of hyperventilation testing and of CPET

Secondary

MeasureTime frame
Assess the diagnosis value of the nijmegen questionnaire.Up to 4 hours
Assess the diagnosis value of the blod gases at rest.up to 4 hours
Assess the diagnosis value of the hyperventilation challenge.Up to 4 hours
Assess the diagnosis value of the CPET.Up to 4 hours

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026